NCT04981808: DiaMonT

Diabetes teleMonitoring of Patients in Insulin Therapy

Completed NA Last updated 31 January 2024

What this trial tests

NA trial testing Telemonitoring in Type 2 Diabetes Treated With Insulin in 331 participants. Completed in 24 November 2023.

Timeline

18 August 2021

Primary endpoint
24 November 2023

24 November 2023

Quick facts

Lead sponsor	Aalborg University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	331
Start date	18 August 2021
Primary completion	24 November 2023
Estimated completion	24 November 2023
Sites	1 location across Denmark

Drugs / interventions tested

• Telemonitoring

Conditions studied

• Type 2 Diabetes Treated With Insulin — all drugs for Type 2 Diabetes Treated With Insulin →

Sponsor

Aalborg University Hospital

Who can join

18 and older, any sex, with Type 2 Diabetes Treated With Insulin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial is an open-label randomized controlled trial. Patients with T2D on insulin therapy will be randomized to a telemonitoring group (intervention) and a usual care group (control). The telemonitoring group will use various devices at home. Hospital staff will monitor their data for a period of three months.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The Diabetes teleMonitoring of patients in insulin Therapy (DiaMonT) trial: study protocol for a randomized controlled trial.
   Hangaard S, Kronborg T, Hejlesen O, Aradóttir TB, et al · · 2022 · cited 13× · PMID 36476605 · DOI 10.1186/s13063-022-06921-6
2. Prediction of Hypoglycemia From Continuous Glucose Monitoring in Insulin-Treated Patients With Type 2 Diabetes Using Transfer Learning on Type 1 Diabetes Data: A Deep Transfer Learning Approach.
   Thomsen HB, Jakobsen MM, Hecht-Pedersen N, Jensen MH, et al · · 2025 · cited 6× · PMID 38014538 · DOI 10.1177/19322968231215324
3. Identifying the Relationship Between Continuous Glucose Monitor Time in Range and Basal Insulin Adherence in People With Type 2 Diabetes.
   Nørlev JTD, Kronborg T, Jensen MH, Vestergaard P, et al · · 2026 · cited 2× · PMID 39523580 · DOI 10.1177/19322968241296828
4. The intelligent diabetes telemonitoring using decision support to treat patients on insulin therapy (DiaTRUST) trial: study protocol for a randomized controlled trial.
   Thomsen CHN, Nørlev JTD, Hangaard S, Jensen MH, et al · · 2024 · cited 2× · PMID 39511648 · DOI 10.1186/s13063-024-08588-7
5. A Three-Step Data-Driven Methodology to Assess Adherence to Basal Insulin Therapy in Patients With Insulin-Treated Type 2 Diabetes.
   Nørlev JTD, Kronborg T, Jensen MH, Vestergaard P, et al · · 2025 · cited 2× · PMID 38158583 · DOI 10.1177/19322968231222007
6. Increased Glycemic Variability in Patients With Chronic Pancreatitis and Diabetes Compared to Type 2 Diabetes.
   Davidsen L, Jensen MH, Kronborg T, Hangaard S, et al · · 2025 · cited 1× · PMID 40682262 · DOI 10.1177/19322968251356239
7. From data to insights: a tool for comprehensive Quantification of Continuous Glucose Monitoring (QoCGM).
   Cichosz S, Hangaard S, Kronborg T, Vestergaard P, et al · · 2025 · cited 1× · PMID 40511383 · DOI 10.7717/peerj.19501
8. Understanding insulin dose deviations in people with type 2 diabetes receiving telemonitoring.
   Nørlev JTD, Kronborg T, Jensen MH, Vestergaard P, et al · · 2025 · PMID 41058351 · DOI 10.1016/j.pcd.2025.10.001